Compare Stocks

→ top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYCN Cyclerion Therapeutics	$2.83 -7.2%	$3.09	$1.75 ▼ $6.75	$8.27M	1.84	4,065 shs	717 shs
EMMA Emmaus Life Sciences	$0.09	$0.11	$0.05 ▼ $0.34	$5.70M	1.61	3,957 shs	50 shs
HOOK Hookipa Pharma	$0.85 +10.4%	$0.74	$0.41 ▼ $2.05	$75.70M	1.02	574,477 shs	10.42 million shs
IMRA IMARA		$17.12	$0.97 ▼ $6.32	$165.80M	1.09	138,364 shs	271,700 shs
LCI Lannett		$1.54	$0.64 ▼ $3.72	$7.38M	0.95	92,067 shs	280,600 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYCN Cyclerion Therapeutics	+2.17%	-12.92%	-6.60%	-4.71%	-49.25%
EMMA Emmaus Life Sciences	+8.57%	-12.09%	-2.91%	-4.67%	-70.59%
HOOK Hookipa Pharma	+11.11%	+11.48%	+20.98%	+19.72%	-10.62%
IMRA IMARA	0.00%	0.00%	0.00%	0.00%	0.00%
LCI Lannett	0.00%	0.00%	0.00%	0.00%	0.00%

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HOOK Hookipa Pharma	3.6113 of 5 stars	3.5	5.0	0.0	0.0	3.7	1.7	1.3
IMRA IMARA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LCI Lannett	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	N/A	N/A	N/A	N/A
HOOK Hookipa Pharma	3.00	Buy	$5.17	507.84% Upside
IMRA IMARA	N/A	N/A	N/A	N/A
LCI Lannett	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest LCI, EMMA, CYCN, HOOK, and IMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/25/2024	HOOK Hookipa Pharma	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
3/25/2024	HOOK Hookipa Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.50
1/30/2024	HOOK Hookipa Pharma	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $5.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYCN Cyclerion Therapeutics	$1.62M	4.73	N/A	N/A	$4.62 per share	0.61
EMMA Emmaus Life Sciences	$18.39M	0.31	N/A	N/A	($0.69) per share	-0.13
HOOK Hookipa Pharma	$20.13M	4.18	N/A	N/A	$0.91 per share	0.93
IMRA IMARA	N/A	N/A	N/A	75.24	$3.44 per share	N/A
LCI Lannett	$340.58M	0.00	N/A	N/A	($23.34) per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYCN Cyclerion Therapeutics	-$5.26M	-$5.51	N/A	∞	N/A	N/A	-111.79%	-74.10%	5/9/2024 (Estimated)
EMMA Emmaus Life Sciences	-$10.62M	-$0.10	N/A	∞	N/A	-16.66%	N/A	-9.73%	N/A
HOOK Hookipa Pharma	-$81.58M	-$0.88	N/A	N/A	N/A	-405.28%	-72.30%	-40.51%	5/9/2024 (Estimated)
IMRA IMARA	$1.49M	$0.05	126.40	N/A	N/A	N/A	2.12%	2.00%	N/A
LCI Lannett	-$231.62M	-$18.88	N/A	N/A	N/A	-62.40%	N/A	-13.39%	N/A

Latest LCI, EMMA, CYCN, HOOK, and IMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/22/2024	Q4 2023	HOOK Hookipa Pharma	-$0.20	-$0.11	+$0.09	N/A	$3.60 million	$7.41 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	N/A	N/A	N/A	N/A	N/A
HOOK Hookipa Pharma	N/A	N/A	N/A	N/A	N/A
IMRA IMARA	N/A	N/A	N/A	N/A	N/A
LCI Lannett	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYCN Cyclerion Therapeutics	N/A	3.85	3.85
EMMA Emmaus Life Sciences	N/A	0.15	0.12
HOOK Hookipa Pharma	N/A	3.50	3.50
IMRA IMARA	N/A	48.98	48.98
LCI Lannett	N/A	2.23	1.39

Ownership

Institutional Ownership

Company	Institutional Ownership
CYCN Cyclerion Therapeutics	75.62%
EMMA Emmaus Life Sciences	7.42%
HOOK Hookipa Pharma	63.88%
IMRA IMARA	49.28%
LCI Lannett	40.28%

Insider Ownership

Company	Insider Ownership
CYCN Cyclerion Therapeutics	13.10%
EMMA Emmaus Life Sciences	35.00%
HOOK Hookipa Pharma	5.82%
IMRA IMARA	37.30%
LCI Lannett	13.12%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CYCN Cyclerion Therapeutics	1	2.71 million	2.36 million	No Data
EMMA Emmaus Life Sciences	54	61.85 million	40.20 million	Not Optionable
HOOK Hookipa Pharma	56	98.95 million	93.19 million	Optionable
IMRA IMARA	41	26.23 million	16.45 million	Not Optionable
LCI Lannett	810	10.77 million	9.35 million	Optionable

LCI, EMMA, CYCN, HOOK, and IMRA Headlines

Source	Headline
	Levothyroxine Dosage and the Limitations of Current Bioequivalence Standards medscape.com - April 7 at 7:19 PM
	‘We lost a good friend;’ Coweta County deputy ran over, killed by Alabama officer identified wsbradio.com - January 6 at 1:47 PM
	Insider Traders Made Easy Money on Stock Offerings tradersmagazine.com - October 2 at 10:42 AM
	Lucky Core Industries Ltd. wsj.com - September 20 at 10:13 PM
	Lannett (LCI) Stock Sinks on Lowered Guidance, Canaccord Downgrade thestreet.com - September 15 at 12:54 PM
	Generic-Drugs Antitrust Case Expanded to Include 18 Companies courthousenews.com - August 2 at 5:40 AM
	Lannett official: Bankruptcy won’t affect Seymour facility tribtown.com - May 12 at 7:02 PM
	Lannett official: Bankruptcy won't affect Seymour facility - Seymour Tribune news.google.com - May 12 at 3:54 AM
	Societal CDMO Reports First Quarter 2023 Financial Results - Yahoo Finance news.google.com - May 11 at 7:52 AM
	Lannett files prepackaged Chapter 11 cases - Drug Store News news.google.com - May 11 at 7:52 AM
	Volunteers complete projects for Jackson County United Way’s 27th ... - Seymour Tribune news.google.com - May 10 at 8:47 AM
	Around the nation: Biden administration warns against medical ... - The Daily Briefing news.google.com - May 9 at 12:45 PM
	Global Methylphenidate Drug Market Size Emerging Trends and Will ... - Cottonwood Holladay Journal news.google.com - May 9 at 7:45 AM
	Global Drugs of UDCA Market Size Analysis, Share, Application ... - The Northwestern Examiner news.google.com - May 8 at 10:52 AM
	Ergocalciferol Market Statistical Forecast, Trade Analysis 2023 - Sanofi S.A., Orit Laboratories LLC, Lannett - openPR news.google.com - May 8 at 10:52 AM
	Generic Drugmaker Lannett Hits Ch. 11 With $700M In Debt - Law360 news.google.com - May 5 at 5:16 PM
	Padagis Achieves A US First With Budesonide Foam Launch - Generics Bulletin news.google.com - May 5 at 12:16 PM
	Spinal Cord Injury Therapeutics Market Forecast to Grow at Steady ... - Digital Journal news.google.com - May 5 at 7:13 AM
	Dicyclomine HCl Market to Witness Astonishing Growth by 2029 ... - Digital Journal news.google.com - May 5 at 7:13 AM
	Claudie Jackson Obituary (2023) - Sylacauga, AL - The Daily Home - Legacy.com news.google.com - May 4 at 11:56 PM
	Lannett bankruptcy; CVS turns away from acquisitions: The National Observer May 4, 2023 - The Business Journals news.google.com - May 4 at 6:55 PM
	Lannett Seeking Fast Run Through $600M Reorg - Law360 news.google.com - May 4 at 6:55 PM
	Lannett announces restructuring - Drug Store News news.google.com - May 4 at 6:55 PM
	Thyroid Gland Disorder Treatment Market Trends 2023: Key Players ... - PharmiWeb.com news.google.com - May 4 at 8:53 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cyclerion Therapeutics

NASDAQ:CYCN

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Emmaus Life Sciences

OTCMKTS:EMMA

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

Hookipa Pharma

NASDAQ:HOOK

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

IMARA

NASDAQ:IMRA

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Lannett

NYSE:LCI

Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial